Testing IBI3028 for Advanced Solid Tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced or metastatic solid tumor (cancer that has spread or cannot be surgically removed)
- You are 18 years or older and in good enough general health to participate (ECOG score 0–1)
- Your blood counts, liver, kidney, heart, and lung function meet specific safety thresholds based on recent lab tests
- You have at least one tumor that can be measured on imaging scans within the past 28 days
- You have not received certain cancer treatments recently (chemotherapy within 3 weeks, immunotherapy within 4 weeks, targeted therapy within 2 weeks)
- You agree to use effective birth control for 4–7 months after your last dose if you can have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.